Host: The Japanese Pharmacological Society
Name : The 95th Annual Meeting of the Japanese Pharmacological Society
Number : 95
Location : Fukuoka
Date : March 07, 2022 - March 09, 2022
Discovery of receptor activator of NF-κB ligand (RANKL) gave a great impact on identification of the mechanisms regulating osteoclast differentiation and function, establishment of research field bridging bone and the immune system (osteoimmunology), and development of a fully human anti-RANKL neutralizing antibody (denosumab). Soluble RANKL and anti-RANKL antibody have been used in vitro and in vivo as valuable research tools. We have reported a novel and rapid bone loss model by administration of glutathione-S transferase (GST)-RANKL to mice, and continuous inhibition of RANKL for several weeks by a single injection of a denosumab-like anti-mouse RANKL neutralizing monoclonal antibody (OYC1) to mice. It is known that RANKL is a multifunction protein that plays a variety of roles such as regulation of bone metabolism. For example, exploration of its pivotal role in immunology is a recent topic of increasing interest. In this presentation I will talk about the discovery of RANKL and the current and future impact of its research.
